Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aytu Biopharma (AYTU) Prepaid Assets (2016 - 2025)

Historic Prepaid Assets for Aytu Biopharma (AYTU) over the last 16 years, with Q4 2025 value amounting to $6.6 million.

  • Aytu Biopharma's Prepaid Assets fell 8947.39% to $6.6 million in Q4 2025 from the same period last year, while for Dec 2025 it was $6.6 million, marking a year-over-year decrease of 8947.39%. This contributed to the annual value of $5.6 million for FY2025, which is 1061.41% up from last year.
  • As of Q4 2025, Aytu Biopharma's Prepaid Assets stood at $6.6 million, which was down 8947.39% from $5.2 million recorded in Q3 2025.
  • Over the past 5 years, Aytu Biopharma's Prepaid Assets peaked at $71.1 million during Q2 2023, and registered a low of $5.1 million during Q2 2024.
  • For the 5-year period, Aytu Biopharma's Prepaid Assets averaged around $16.6 million, with its median value being $8.0 million (2022).
  • As far as peak fluctuations go, Aytu Biopharma's Prepaid Assets surged by 86378.31% in 2023, and later tumbled by 9282.91% in 2024.
  • Aytu Biopharma's Prepaid Assets (Quarter) stood at $11.3 million in 2021, then rose by 6.12% to $12.0 million in 2022, then crashed by 32.4% to $8.1 million in 2023, then soared by 677.95% to $63.1 million in 2024, then tumbled by 89.47% to $6.6 million in 2025.
  • Its Prepaid Assets stands at $6.6 million for Q4 2025, versus $5.2 million for Q3 2025 and $5.6 million for Q2 2025.